Mesenchymal stem cells from bone marrow of patients with drug-resistant tuberculosis for cellular therapy
https://doi.org/10.58708/2074-2088.2023-2(30)-40-45
Abstract
In this study, we evaluated the proliferative capacity of mesenchymal stem cells (MSCs) from the bone marrow of patients with drug-resistant tuberculosis (DR-TB) and selected the optimal conditions for obtaining autologous MSCs transplant. The results of the expansion of MSCs from 42 patients with DR-TB in medium with 10% FBS demonstrated low proliferative potential for of these cells compared with MSCs from 47 donors. MSCs content in 1 ml of bone marrow of patients was also lower. A relationship was found between the amount of MSCs in the primary culture and in the finished product, and with a small number of cells in the primary culture, we used 5% platelet lysate instead of 10% FTS, which made it possible to obtain a high dose of MSCs in the transplant.
About the Authors
Y. Isaikina
ГУ «РНПЦ детской онкологии, гематологии и иммунологии»
Belarus
Belarus
V. Solodovnikova
ГУ «РНПЦ пульмонологии и фтизиатрии»
Belarus
Belarus
R. Frolova
ГУ «РНПЦ детской онкологии, гематологии и иммунологии»
Belarus
Belarus
U. Savich
ГУ «РНПЦ детской онкологии, гематологии и иммунологии»
Belarus
Belarus
H. Zhernasechanka
ГУ «РНПЦ детской онкологии, гематологии и иммунологии»
Belarus
Belarus
A. Skrahina
ГУ «РНПЦ пульмонологии и фтизиатрии»
Belarus
Belarus
References
1. Secretome of Mesenchymal Stromal Cells Prevents Myofibroblasts Differentiation by Transferring Fibrosis-Associated microRNAs within Extracellular Vesicles // N. Basalova, [et al.] / Cells. – 2020. – Vol. 9, № 5. https://doi.org/10.3390/cells9051272.
2. Mora, A.L. Aging and lung injury repair: a role for bone marrow derived mesenchymal stem cells // A.L. Mora, M. Rojas. / J Cell Biochem. – 2008. – Vol. 105. – P. 641-647.
3. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial / M.K. Glassberg [et al.] // Chest. – 2017. – Vol. 151. – P. 971-981.
4. Mesenchymal stem cells secrete immunologically active exosomes// Zhang B [et al.] / Stem Cells Dev. – 2014. – Vol23, №11. – P. 1233-1244.
5. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo // A.Bartholomew [et al.] / Exp. Hematol. – 2002. – Vol. 30. – Р. 42-48.
6. Mesenchymal stem cells inhibit proliferation of lymphoid origin haematopoietic tumour cells by inducing cell cycle arrest / V. H. Sarmadi [et al.] // Med. J. Malaysia. – 2010. – Vol. 65, № 3. – Р. 209-214.
7. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion / J. Gao [et al.] // Cells. – 2001. – Vol.169, №1. – P.12-20.
8. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the antiinlammatory protein TSG- 6 / R.H. Lee [et al.] // Cell Stem Cell. – 2009. – V.5. – P. 54-63.
9. Systemic and local delivery of mesenchymal stem cells for heart renovation: challenges and innovations / Z. Liu [et al.] // Eur J Pharmacol. – 2020. – Vol. 876. https://doi.org/10.1016/j.ejphar.2020.173049.
10. Ростстимулирующая активность препаратов тромбоцитов в отношении мезенхимальных стволовых клеток in vitro / С.И. Игнатенко, С.М. Космачева, М.П. Потапнев // Весцi/Известия НАНБ, сер. мед. наук. – 2016. – Т. 1. – C. 52-58.
11. Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability / R. Crespo-Diaz [et al.] // Cell Transpl. – 2011. – Vol.20. – P. 797-811. https://doi.org/10.3727/096368910X543376
Review
For citations:
Isaikina Y., Solodovnikova V., Frolova R., Savich U., Zhernasechanka H., Skrahina A. Mesenchymal stem cells from bone marrow of patients with drug-resistant tuberculosis for cellular therapy. Medical and Biological Problems of Life Activity. 2023;(2):40-45. (In Russ.) https://doi.org/10.58708/2074-2088.2023-2(30)-40-45
Views: 245
Email this article 